William Blair & Company’s Sanofi Contingent Value Rights GCVRZ Stock Holding History

William Blair & Company’s Portfolio GCVRZ Stock Details GCVRZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-14,032	Closed	-$12K	–	1819
2019 Q4	$12K	Hold	14,032	–	–	﹤0.01%	1625
2019 Q3	$8K	Hold	14,032	–	–	﹤0.01%	1621
2019 Q2	$7K	Sell	14,032 -350	-2%	-$175	﹤0.01%	1668
2019 Q1	$6K	Buy	14,382 +350	+2%	+$163	﹤0.01%	1654
2018 Q4	$7K	Hold	14,032	–	–	﹤0.01%	1597
2018 Q3	$7K	Sell	14,032 -628	-4%	-$337	﹤0.01%	1589
2018 Q2	$7K	Buy	14,660 +14,005	+2,138%	+$6.53K	﹤0.01%	1556
2018 Q1	$0	Buy	+655	New	+$264	﹤0.01%	1654
2017 Q4	–	Sell	-655	Closed	–	–	1487
2017 Q3	$0	Buy	+655	New	+$243	﹤0.01%	1642

William Blair & Company's GCVRZ Position: Q1 2020 in Review

William Blair & Company sold out of Sanofi Contingent Value Rights (GCVRZ) in Q1 2020, closing a stake of 14,032 shares — an estimated $12K sold.

William Blair & Company first reported a position in GCVRZ in Q3 2017 and held it in 9 quarters. The position peaked at $12K in Q4 2019. 2 funds tracked by Wall St. Rank hold GCVRZ as of Q1 2020.

William Blair & Company reported no remaining Sanofi Contingent Value Rights position as of Q1 2020 after selling out during the quarter.
William Blair & Company sold 14,032 Sanofi Contingent Value Rights shares in Q1 2020, an estimated $12K.
William Blair & Company first reported a position in Sanofi Contingent Value Rights in Q3 2017 and held it in 9 quarters.
William Blair & Company's Sanofi Contingent Value Rights position peaked at $12K in Q4 2019.
2 funds tracked by Wall St. Rank held Sanofi Contingent Value Rights as of Q1 2020.

Based on William Blair & Company's 13F filing for Q1 2020, filed 11 May 2020.